Notice of Funding Opportunity Purpose
National Institutes of Health
Description
The grant opportunity is designed to extend current U19 awards to support the initiation of first-in-human clinical trials involving genome editing. It is part of the NIH Somatic Cell Genome Editing program and specifically requires the inclusion of a clinical trial, differentiating it from the earlier funding opportunity RFA-RM-22-015.
The NOFO aims to expand the scope of existing U19 awards to include first in human genome editing clinical trials. This opportunity is part of the NIH Somatic Cell Genome Editing program and requires a clinical trial, unlike the previous RFA-RM-22-015.
Source
Grant ID
RFA-RM-24-008
Agency
National Institutes of Health
Subcategory/Subagency
Office of Strategic Coordination (Common Fund)
Key Dates
Opportunity Released
November 21, 2024
Eligibility
The following categories of applicants are invited to apply:
- Limited competition: Only existing SCGE IND-enabling Studies of Somatic Genome Editing Therapeutic Leads recipient(s) — awardees of RFA-RM-22-015 (active U19 awards)
- U.S. Federal Government — Eligible Agencies of the Federal Government
- U.S. Territory or Possession
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-domestic (non-U.S.) components of U.S. Organizations (eligible)
Similar opportunities
- Genomic Resources for Research and Clinical Use
National Institutes of Health
- NIH Pathway to Independence Award (K99/R00)
National Institutes of Health
- Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders
National Institutes of Health
- Bioengineering Research Grant (EBRG) Applications
National Institutes of Health
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE)
National Institutes of Health